Oncology is arguably the fastest-moving clinical specialty in medicine. The FDA approved 67 new oncology drugs and indications in 2024 alone. NCCN guidelines update dozens of times per year. A practicing oncologist who stops reading for six months may return to find that the standard of care in several tumor types has fundamentally changed. This guide covers practical systems for keeping up.
No other specialty has experienced the pace of evidence-based change that oncology has since 2010. The arrival of immune checkpoint inhibitors, CAR-T therapies, bispecific antibodies, and targeted agents with companion diagnostics has created a literature environment where landmark trials are reported at every major conference and FDA accelerated approvals regularly precede full trial publication.
The practical consequence: an oncologist's reading strategy cannot be static. The journals, meetings, and surveillance mechanisms that were adequate in 2015 are insufficient in 2026.
Rather than monitoring all oncology journals, subspecialty focus is the most efficient approach:
| Subspecialty | Primary journals |
|---|---|
| General oncology | Journal of Clinical Oncology (JCO), NEJM, JAMA Oncology |
| Thoracic / lung | Journal of Thoracic Oncology, Lung Cancer |
| GI oncology | Gastroenterology, Annals of Oncology, JCO |
| Breast oncology | JCO, Lancet Oncology, Breast Cancer Research and Treatment |
| Hematology | Blood, JCO, Leukemia, Haematologica |
| Genitourinary | European Urology, JCO, JAMA Oncology |
| Neuro-oncology | Neuro-Oncology, JCO |
In oncology, FDA approval announcements are often clinically actionable before the underlying trial is published. A patient who is progression-free on current treatment may ask about a newly approved regimen you haven't yet read about. Mechanisms for capturing FDA approvals in real time:
Important: FDA accelerated approval does not guarantee confirmatory trial completion or eventual full approval. Tracking which approvals are accelerated vs. traditional, and whether confirmatory trials have reported, requires active surveillance. Several accelerated approvals have been withdrawn in recent years after confirmatory trials failed.
NCCN Clinical Practice Guidelines in Oncology are updated continuously throughout the year rather than on an annual cycle. Each update generates a version number and a summary of changes. For practicing oncologists, a systematic review of NCCN guideline updates in your tumor types — ideally monthly — is the most clinically impactful reading you can do.
NCCN now provides a "What's New" feature that shows changes between versions, making it practical to review only what changed rather than reading entire guidelines from scratch. Bookmark the "Physician Resources" and "What's New" section for each guideline relevant to your practice.
The highest-impact oncology data are almost always first presented at four conferences:
The most efficient conference reading strategy: read the ASCO and ESMO late-breaking abstract session presentations (typically 10 to 15 presentations each), which represent the highest-impact trials of the year. Everything else can be accessed on demand through abstract books and online presentations.
The biomarker-driven nature of modern oncology means that knowing the drug is insufficient — understanding which patients respond to which drugs based on which biomarkers is the essential clinical knowledge. The PD-L1 expression, MSI-H/dMMR, TMB, HER2, KRAS, BRAF, ALK/ROS1/RET/NTRK — the list of actionable biomarkers and their treatment implications expands every year. Molecular tumor board discussions and tumor-specific biomarker literature are essential components of keeping up in this area.
MDInformed curates the five most clinically relevant papers from 35 million publications and delivers them as a structured digest — free forever.
Join the waitlist →